Equities research analysts expect that Agenus Inc (NASDAQ:AGEN) will post sales of $15.58 million for the current quarter, according to Zacks. Two analysts have issued estimates for Agenus’ earnings, with the highest sales estimate coming in at $27.60 million and the lowest estimate coming in at $3.56 million. Agenus reported sales of $5.58 million during the same quarter last year, which indicates a positive year over year growth rate of 179.2%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Agenus will report full-year sales of $15.58 million for the current financial year, with estimates ranging from $38.08 million to $62.10 million. For the next fiscal year, analysts expect that the firm will post sales of $28.53 million per share, with estimates ranging from $21.46 million to $35.60 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Agenus.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The firm’s quarterly revenue was down 24.4% compared to the same quarter last year.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut Agenus from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. BidaskClub cut Agenus from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine cut Agenus from a “sell” rating to a “strong sell” rating in a research report on Friday, December 29th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $5.81.

In related news, insider Karen Valentine sold 8,358 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the completion of the transaction, the insider now directly owns 109,879 shares of the company’s stock, valued at $380,181.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 20,514 shares of company stock valued at $70,978 over the last three months. Insiders own 7.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Agenus by 5.2% during the second quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares during the last quarter. Artal Group S.A. boosted its position in Agenus by 25.0% during the third quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares during the last quarter. Northern Trust Corp boosted its position in Agenus by 4.1% during the second quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after purchasing an additional 37,239 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in Agenus by 12.8% during the third quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 70,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in Agenus by 11.4% during the second quarter. Wells Fargo & Company MN now owns 520,142 shares of the biotechnology company’s stock valued at $2,033,000 after purchasing an additional 53,343 shares during the last quarter. 37.89% of the stock is owned by hedge funds and other institutional investors.

Agenus (NASDAQ AGEN) traded down $0.09 during mid-day trading on Thursday, hitting $3.65. The stock had a trading volume of 652,147 shares, compared to its average volume of 1,412,617. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39. The firm has a market capitalization of $325.38, a PE ratio of -3.12 and a beta of 2.11. Agenus has a 52 week low of $3.20 and a 52 week high of $5.45.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/31/zacks-analysts-expect-agenus-inc-agen-will-announce-quarterly-sales-of-15-58-million.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.